TY - JOUR
T1 - Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease
AU - Morishita, Tsuyoshi
AU - Tsutsui, Masato
AU - Shimokawa, Hiroaki
AU - Tasaki, Hiromi
AU - Suda, Osamu
AU - Kobayashi, Kengo
AU - Horiuchi, Masataka
AU - Okuda, Haruhito
AU - Tsuda, Yuki
AU - Yanagihara, Nobuyuki
AU - Nakashima, Yasuhide
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - The present study was designed to examine whether long-term blockade of angiotensin-converting enzyme (ACE) with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease (CAD). Twelve patients with proven CAD were randomly divided in two groups; one group received perindopril (8 mg/day, p.o.) for 3 months and another group served as a control. To evaluate anti-ischemic effects of perindopril, dobutamine stress echocardiography was performed before and 3 months after the treatment in a double-blind manner. Long-term treatment with perindopril significantly ameliorated the dobutamine-induced myocardial ischemia, as evaluated by time to the onset of symptoms, magnitude of electrocardiographic ST-segment changes, and left ventricular wall motion score (all P<0.05). The treatment significantly decreased serum ACE activities (P<0.01) and increased plasma bradykinin concentrations (P<0.05). The extent of reduction of left ventricular wall motion score by perindopril was closely correlated with that of inhibition of serum ACE activities (P<0.01) and with that of increase in plasma bradykinin concentrations (P<0.05). By contrast, no such beneficial changes were noted in the control group. These results provide the first evidence that long-term treatment with perindopril exerts anti-ischemic effects on the myocardial ischemia induced by increased myocardial oxygen demand in patients with CAD.
AB - The present study was designed to examine whether long-term blockade of angiotensin-converting enzyme (ACE) with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease (CAD). Twelve patients with proven CAD were randomly divided in two groups; one group received perindopril (8 mg/day, p.o.) for 3 months and another group served as a control. To evaluate anti-ischemic effects of perindopril, dobutamine stress echocardiography was performed before and 3 months after the treatment in a double-blind manner. Long-term treatment with perindopril significantly ameliorated the dobutamine-induced myocardial ischemia, as evaluated by time to the onset of symptoms, magnitude of electrocardiographic ST-segment changes, and left ventricular wall motion score (all P<0.05). The treatment significantly decreased serum ACE activities (P<0.01) and increased plasma bradykinin concentrations (P<0.05). The extent of reduction of left ventricular wall motion score by perindopril was closely correlated with that of inhibition of serum ACE activities (P<0.01) and with that of increase in plasma bradykinin concentrations (P<0.05). By contrast, no such beneficial changes were noted in the control group. These results provide the first evidence that long-term treatment with perindopril exerts anti-ischemic effects on the myocardial ischemia induced by increased myocardial oxygen demand in patients with CAD.
KW - Angiotensin-converting enzyme inhibitor
KW - Coronary artery disease
KW - Dobutamine stress echocardiography
KW - Myocardial ischemia
KW - Perindopril
UR - http://www.scopus.com/inward/record.url?scp=0036173278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036173278&partnerID=8YFLogxK
U2 - 10.1254/jjp.88.100
DO - 10.1254/jjp.88.100
M3 - Article
C2 - 11855668
AN - SCOPUS:0036173278
VL - 88
SP - 100
EP - 107
JO - Japanese Journal of Pharmacology
JF - Japanese Journal of Pharmacology
SN - 0021-5198
IS - 1
ER -